Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Axcel VI and Currentum in connection with the acquisitions of Gullikssons El, Elkalkyl och Elprojektering and Reglerab
Mandate

Vinge advises Axcel VI and Currentum in connection with the acquisitions of Gullikssons El, Elkalkyl och Elprojektering and Reglerab

September 13, 2022 Employment and Benefits M&A Banking and Finance Real Estate and Construction

Vinge advises Axcel VI and the Currentum Group in connection with the acquisitions of J. Gullikssons El Aktiebolag, Elkalkyl och Elprojektering i Sverige AB and Reglerab AB.

The companies provide services in planning, installation and service in the electrical and construction sectors and are based in Stockholm and Mälardalen. Together, the companies have a turnover of approximately SEK 155 million and approximately 100 employees. Following the acquisitions, Currentum is expected to have a turnover of approximately SEK 3 billion and will engage just over 1,000 employees.

Vinge’s team consisted of partner Christina Kokko together with Carl Fredrik Wachtmeister, Linnea Petersson and Philip Moré (M&A), Isak Willborg (Construction), Sara Strandberg (Employment), Calle Tengwall Pagels (Financing), Frida Ställborn (Real Estate) and Anna Ekdahl Roos (project assistant).

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

 Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025